do peptides work when taken by mouth?

updated

a few engineered peptides work by mouth. semaglutide tablets need an absorption enhancer and an empty stomach, and absorb a small fraction of what an injection delivers.

verdict: only engineered exceptions; the general claim is unsupported (engineered oral peptides only / general oral use unproven)

quick answer

only some, and only by design. semaglutide tablets are FDA-approved, but the tablet carries an absorption enhancer, salcaprozate sodium (SNAC). the tablet label estimates that about 0.4 to 1 percent of the semaglutide in Rybelsus and 1 to 2 percent in Ozempic tablets reach the bloodstream; the Ozempic injection label gives 89 percent after injection. larazotide takes another route: it is built to act inside the gut instead of being absorbed. neither shows that other peptides survive being swallowed.

the evidence

an oral peptide drug exists. (supported)

semaglutide tablets are FDA-approved. the label pairs semaglutide with salcaprozate sodium (SNAC), an absorption enhancer, and says absorption happens mainly in the stomach.

it works by engineering, not by default. (gap)

the label requires an empty stomach, a small amount of plain water and a wait before food, drink or other oral medicines, and says its two tablet brands, Rybelsus and Ozempic tablets, are not substitutable milligram for milligram. even then it estimates about 0.4 to 1 percent absorption for Rybelsus and 1 to 2 percent for Ozempic tablets; the Ozempic injection label gives 89 percent for injected semaglutide.

a gut-acting peptide answers a different question. (risk)

larazotide, an eight-amino-acid peptide given as enteric-coated beads in capsules, is designed to act inside the gut rather than be absorbed. a randomized, placebo-controlled trial in 342 adults with celiac disease found a symptom benefit at the lowest dose only, and the phase 3 was terminated by its sponsor with no results posted.

bottom line

oral delivery belongs to a specific engineered product, so each oral claim needs its own evidence.

scores

  • human evidence for oral peptides: 50 · shown for specific products: semaglutide tablets are FDA-approved, and larazotide's oral trials were mixed
  • absorption mechanism: 2 · percent absorbed: the tablet label estimates about 0.4 to 1 for Rybelsus and 1 to 2 for Ozempic tablets, taken with an enhancer on an empty stomach; the injection label gives 89
  • general-claim gap: 100 · the evidence covers engineered or gut-acting products only; it does not show other peptides surviving digestion
  • gut-acting design: 100 · larazotide is designed to act inside the gut without being absorbed (Slifer 2021)

sources

  1. Rybelsus and Ozempic tablets US prescribing information, revised January 2026. Current oral semaglutide product label.
  2. Ozempic injection US prescribing information, revised October 2025. Current Ozempic injection label.
  3. Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Am J Physiol Gastrointest Liver Physiol. 2021. PMID 33881350. larazotide acetate identity and tight-junction pharmacology review.
  4. Leffler DA et al. Gastroenterology 2015. larazotide phase 2b in persistent celiac symptoms.
  5. CeDLara phase 3 (NCT03569007), ClinicalTrials.gov. pivotal phase 3, terminated.

keep reading

claim checks

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.